Clinical Trials | December 20, 2022
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Ayúdame3D has become a leading social entity in social technology.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
This partnership stemmed from a successful customer-supplier relationship spanning several years.
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Subscribe To Our Newsletter & Stay Updated
